<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_glycine" title="Combined Supplementation with Glycine and Tryptophan Reduces Purine-Induced Serum Uric Acid Elevation by Accelerating Urinary Uric Acid Excretion: A Randomized, Single-Blind, Placebo-Controlled, Crossover Study" shortTitle="glycine" author="Shunji Oshima, Sachie Shiiya, Yasunori Nakamura" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6643/11/11/2562/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
4.	LS	4.
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
This	DT	this
study	NN	study
examined	VBD	examine
whether	IN	whether
the	DT	the
combined	VBN	combine
administration	NN	administration
of	IN	of
6.0	CD	6.0
g	NNS	gram
of	IN	of
glycine	NN	glycine
and	CC	and
0.4	CD	0.4
g	NNS	gram
of	IN	of
tryptophan	NN	tryptophan
suppressed	VBD	suppress
the	DT	the
elevation	NN	elevation
in	IN	in
serum	NN	serum
uric	NN	uric
acid	NN	acid
levels	NNS	level
induced	VBN	induce
by	IN	by
purine	NN	purine
ingestion	NN	ingestion
and	CC	and
increased	VBD	increase
urinary	JJ	urinary
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
.	.	.
</s>
<s type="decl">
The	DT	the
amino	NN	amino
acid	NN	acid
doses	NNS	dose
used	VBN	use
for	IN	for
single	JJ	single
ingestion	NN	ingestion
were	VBD	be
based	VBN	base
on	IN	on
those	DT	this
used	VBN	use
in	IN	in
continual	JJ	continual
supplementation	NN	supplementation
.	.	.
</s>
<s type="decl">
Both	CC	both
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
are	VBP	be
present	JJ	present
in	IN	in
dietary	JJ	dietary
proteins	NNS	protein
that	WDT	that
are	VBP	be
ingested	VBN	ingest
in	IN	in
normal	JJ	normal
daily	JJ	daily
living	NN	living
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
glycine	NN	glycine
at	IN	at
doses	NNS	dose
of	IN	of
up	IN	up
to	IN	to
90	CD	90
g	NNS	gram
per	IN	per
day	NN	day
administered	VBN	administer
over	IN	over
several	JJ	several
weeks	NNS	week
were	VBD	be
reported	VBN	report
no	DT	no
serious	JJ	serious
adverse	JJ	adverse
effects	NNS	effect
.	.	.
</s>
<s type="decl">
The	DT	the
oral	JJ	oral
administration	NN	administration
of	IN	of
up	IN	up
to	IN	to
5.0	CD	5.0
g	NNS	gram
of	IN	of
l-tryptophan	NN	l-tryptophan
per	IN	per
day	NN	day
did	VBD	do
not	RB	not
lead	VB	lead
to	IN	to
any	DT	any
adverse	JJ	adverse
effects	NNS	effect
in	IN	in
young	JJ	young
adult	JJ	adult
females	NNS	female
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
no	DT	no
adverse	JJ	adverse
effects	NNS	effect
were	VBD	be
attributed	VBN	attribute
to	IN	to
the	DT	the
combined	VBN	combine
administration	NN	administration
of	IN	of
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
in	IN	in
the	DT	the
current	JJ	current
trial	NN	trial
.	.	.
</s>
<s type="decl">
This	DT	this
study	NN	study
confirmed	VBD	confirm
the	DT	the
safety	NN	safety
of	IN	of
combined	VBN	combine
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
supplementation	NN	supplementation
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
current	JJ	current
study	NN	study
demonstrated	VBD	demonstrate
that	IN	that
the	DT	the
combined	VBN	combine
administration	NN	administration
of	IN	of
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
significantly	RB	significantly
suppressed	VBD	suppress
the	DT	the
elevation	NN	elevation
in	IN	in
the	DT	the
serum	NN	serum
uric	NN	uric
acid	NN	acid
levels	NNS	level
caused	VBN	cause
by	IN	by
purine	NN	purine
ingestion	NN	ingestion
in	IN	in
healthy	JJ	healthy
subjects	NNS	subject
.	.	.
</s>
<s type="decl">
The	DT	the
effect	NN	effect
of	IN	of
the	DT	the
combined	VBN	combine
amino	NN	amino
acid	NN	acid
administration	NN	administration
was	VBD	be
stronger	JJR	strong
than	IN	than
that	DT	that
of	IN	of
the	DT	the
same	JJ	same
glycine	NN	glycine
dose	NN	dose
alone	RB	alone
,	,	,
indicating	VBG	indicate
that	IN	that
a	DT	a
small	JJ	small
amount	NN	amount
of	IN	of
tryptophan	NN	tryptophan
provides	VBZ	provide
an	DT	a
additional	JJ	additional
benefit	NN	benefit
to	IN	to
glycine	NN	glycine
alone	RB	alone
in	IN	in
reducing	VBG	reduce
the	DT	the
elevation	NN	elevation
in	IN	in
the	DT	the
serum	NN	serum
uric	NN	uric
acid	NN	acid
levels	NNS	level
after	IN	after
the	DT	the
ingestion	NN	ingestion
of	IN	of
dietary	JJ	dietary
purines	NNS	purine
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
agreement	NN	agreement
with	IN	with
previous	JJ	previous
reports	NNS	report
,	,	,
glycine	NN	glycine
increased	VBD	increase
urinary	JJ	urinary
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
and	CC	and
enhanced	VBD	enhance
urate	NN	urate
clearance	NN	clearance
in	IN	in
the	DT	the
current	JJ	current
study	NN	study
.	.	.
</s>
<s type="decl">
The	DT	the
authors	NNS	author
previously	RB	previously
reported	VBD	report
that	IN	that
continual	JJ	continual
supplementation	NN	supplementation
with	IN	with
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
led	VBD	lead
to	IN	to
an	DT	a
increase	NN	increase
in	IN	in
urinary	JJ	urinary
pH	NN	pH
.	.	.
</s>
<s type="decl">
Glycine	NNP	Glycine
exhibits	VBZ	exhibit
a	DT	a
buffering	VBG	buffer
action	NN	action
and	CC	and
it	PRP	it
is	VBZ	be
often	RB	often
used	VBN	use
as	IN	as
an	DT	a
antacid	NN	antacid
.	.	.
</s>
<s type="decl">
The	DT	the
water	NN	water
solubility	NN	solubility
of	IN	of
uric	NN	uric
acid	NN	acid
increases	VBZ	increase
with	IN	with
increasing	VBG	increase
pH	NN	pH
levels	NNS	level
and	CC	and
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
is	VBZ	be
more	RBR	more
favorable	JJ	favorable
in	IN	in
alkaline	JJ	alkaline
urine	NN	urine
than	IN	than
in	IN	in
acidic	JJ	acidic
urine	NN	urine
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
it	PRP	it
is	VBZ	be
possible	JJ	possible
that	IN	that
the	DT	the
elevation	NN	elevation
in	IN	in
urinary	JJ	urinary
pH	NN	pH
caused	VBN	cause
by	IN	by
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
supplementation	NN	supplementation
enhanced	VBD	enhance
the	DT	the
solubility	NN	solubility
of	IN	of
urinary	JJ	urinary
uric	NN	uric
acid	NN	acid
,	,	,
thereby	RB	thereby
elevating	VBG	elevate
urinary	JJ	urinary
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
and	CC	and
urate	NN	urate
clearance	NN	clearance
.	.	.
</s>
<s type="decl">
Previous	JJ	previous
studies	NNS	study
provide	VBP	provide
physiological	JJ	physiological
,	,	,
physicochemical	JJ	physicochemical
and	CC	and
clinical	JJ	clinical
validation	NN	validation
for	IN	for
the	DT	the
use	NN	use
of	IN	of
citrate	NN	citrate
salt	NN	salt
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
some	DT	some
types	NNS	type
of	IN	of
lithiasis	NN	lithiasis
.	.	.
</s>
<s type="decl">
Citrate	NNP	Citrate
salts	NNS	salt
treatment	NN	treatment
substantially	RB	substantially
increased	VBD	increase
urinary	JJ	urinary
pH	NN	pH
in	IN	in
patients	NNS	patient
with	IN	with
uric	JJ	uric
acid	NN	acid
lithiasis	NN	lithiasis
,	,	,
however	RB	however
,	,	,
there	EX	there
was	VBD	be
no	DT	no
significant	JJ	significant
change	NN	change
in	IN	in
the	DT	the
amount	NN	amount
of	IN	of
urinary	JJ	urinary
uric	NN	uric
acid	NN	acid
.	.	.
</s>
<s type="decl">
The	DT	the
mixture	NN	mixture
of	IN	of
amino	NN	amino
acids	NNS	acid
might	MD	might
be	VB	be
superior	JJ	superior
to	IN	to
citrate	NN	citrate
salts	NNS	salt
in	IN	in
the	DT	the
prevention	NN	prevention
or	CC	or
treatment	NN	treatment
of	IN	of
hyperuricemia	NN	hyperuricemia
.	.	.
</s>
<s type="decl">
Herein	RB	herein
,	,	,
although	IN	although
the	DT	the
elevation	NN	elevation
of	IN	of
urinary	JJ	urinary
pH	NN	pH
induced	VBN	induce
by	IN	by
the	DT	the
ingestion	NN	ingestion
of	IN	of
glycine	NN	glycine
alone	RB	alone
was	VBD	be
not	RB	not
significant	JJ	significant
compared	VBN	compare
with	IN	with
the	DT	the
effects	NNS	effect
of	IN	of
placebo	NN	placebo
,	,	,
glycine	NN	glycine
administration	NN	administration
enhanced	VBN	enhance
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
and	CC	and
urate	NN	urate
clearance	NN	clearance
,	,	,
raising	VBG	raise
the	DT	the
possibility	NN	possibility
of	IN	of
other	JJ	other
mechanisms	NNS	mechanism
.	.	.
</s>
<s type="decl">
Urate	NNP	Urate
transporter	NN	transporter
1	CD	1
(	-LRB-	(
URAT1	NNP	URAT1
)	-RRB-	)
,	,	,
a	DT	a
primary	JJ	primary
reabsorptive	JJ	reabsorptive
urate	NN	urate
transporter	NN	transporter
that	WDT	that
is	VBZ	be
targeted	VBN	target
by	IN	by
pyrazinamide	NN	pyrazinamide
,	,	,
reportedly	RB	reportedly
disables	VBZ	disable
glycine-induced	JJ	glycine-induced
uricosuria	NN	uricosuria
.	.	.
</s>
<s type="decl">
Pyrazinamide	NNP	Pyrazinamide
may	MD	may
reflect	VB	reflect
the	DT	the
enhanced	VBN	enhance
urate	NN	urate
reabsorption	NN	reabsorption
following	VBG	follow
the	DT	the
exchange	NN	exchange
of	IN	of
its	PRP$	its
active	JJ	active
metabolite	NN	metabolite
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
glycine	NN	glycine
may	MD	may
inhibit	VB	inhibit
the	DT	the
reabsorptive	JJ	reabsorptive
action	NN	action
of	IN	of
uric	NN	uric
acid	NN	acid
,	,	,
which	WDT	which
is	VBZ	be
induced	VBN	induce
by	IN	by
URAT1	NNP	URAT1
.	.	.
</s>
<s type="decl">
Further	JJR	further
studies	NNS	study
are	VBP	be
needed	VBN	need
to	TO	to
elucidate	VB	elucidate
the	DT	the
action	NN	action
of	IN	of
glycine	NN	glycine
on	IN	on
URAT1	NNP	URAT1
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
the	DT	the
current	JJ	current
study	NN	study
,	,	,
the	DT	the
supplementation	NN	supplementation
with	IN	with
tryptophan	NN	tryptophan
alone	RB	alone
had	VBD	have
no	DT	no
influence	NN	influence
on	IN	on
urinary	JJ	urinary
pH	NN	pH
,	,	,
urinary	JJ	urinary
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
or	CC	or
urate	NN	urate
clearance	NN	clearance
.	.	.
</s>
<s type="sub">
As	IN	as
the	DT	the
effect	NN	effect
of	IN	of
tryptophan	NN	tryptophan
on	IN	on
URAT1	NNP	URAT1
might	MD	might
be	VB	be
structurally	RB	structurally
difficult	JJ	difficult
,	,	,
tryptophan	NN	tryptophan
might	MD	might
have	VB	have
exerted	VBN	exert
an	DT	a
indirect	JJ	indirect
action	NN	action
against	IN	against
uric	NN	uric
acid	NN	acid
elevation	NN	elevation
via	IN	via
its	PRP$	its
influence	NN	influence
on	IN	on
the	DT	the
action	NN	action
of	IN	of
glycine	NN	glycine
.	.	.
</s>
<s type="sub">
Specifically	RB	specifically
,	,	,
tryptophan	NN	tryptophan
might	MD	might
promote	VB	promote
the	DT	the
direct	JJ	direct
action	NN	action
of	IN	of
glycine	NN	glycine
against	IN	against
uric	NN	uric
acid	NN	acid
elevation	NN	elevation
.	.	.
</s>
<s type="decl">
The	DT	the
maximum	JJ	maximum
serum	NN	serum
levels	NNS	level
of	IN	of
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
are	VBP	be
achieved	VBN	achieve
within	IN	within
an	DT	a
hour	NN	hour
of	IN	of
ingestion	NN	ingestion
,	,	,
which	WDT	which
is	VBZ	be
followed	VBN	follow
by	IN	by
rapid	JJ	rapid
decreases	NNS	decrease
as	IN	as
the	DT	the
amino	NN	amino
acids	NNS	acid
are	VBP	be
metabolized	VBN	metabolize
.	.	.
</s>
<s type="decl">
Glycine	NNP	Glycine
metabolizes	VBZ	metabolize
various	JJ	various
end-products	NNS	end-product
,	,	,
namely	RB	namely
glutathione	NN	glutathione
,	,	,
nucleic	JJ	nucleic
acid	NN	acid
bases	NNS	base
,	,	,
heme	NN	heme
,	,	,
creatine	NN	creatine
and	CC	and
bile	NN	bile
acids	NNS	acid
.	.	.
</s>
<s type="decl">
The	DT	the
increases	NNS	increase
in	IN	in
urinary	JJ	urinary
creatinine	NN	creatinine
excretion	NN	excretion
and	CC	and
creatinine	NN	creatinine
clearance	NN	clearance
following	VBG	follow
the	DT	the
glycine	NN	glycine
challenge	NN	challenge
suggest	VBP	suggest
that	IN	that
glycine	NN	glycine
might	MD	might
be	VB	be
partially	RB	partially
absorbed	VBN	absorb
back	RB	back
and	CC	and
metabolized	VBN	metabolize
to	IN	to
creatinine	NN	creatinine
through	IN	through
creatine	NN	creatine
.	.	.
</s>
<s type="decl">
Conversely	RB	conversely
,	,	,
these	DT	this
urinary	JJ	urinary
parameters	NNS	parameter
did	VBD	do
not	RB	not
change	VB	change
in	IN	in
response	NN	response
to	IN	to
the	DT	the
simultaneous	JJ	simultaneous
supplementation	NN	supplementation
with	IN	with
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
,	,	,
suggesting	VBG	suggest
the	DT	the
suppression	NN	suppression
of	IN	of
the	DT	the
conversion	NN	conversion
of	IN	of
glycine	NN	glycine
to	IN	to
creatinine	NN	creatinine
by	IN	by
tryptophan	NN	tryptophan
.	.	.
</s>
<s type="decl">
In	IN	in
fact	NN	fact
,	,	,
the	DT	the
increases	NNS	increase
in	IN	in
the	DT	the
serum	NN	serum
glycine/creatinine	NN	glycine/creatinine
ratio	NN	ratio
and	CC	and
urinary	JJ	urinary
glycine	NN	glycine
excretion	NN	excretion
were	VBD	be
more	RBR	more
pronounced	VBN	pronounce
in	IN	in
response	NN	response
to	IN	to
supplementation	NN	supplementation
with	IN	with
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
than	IN	than
with	IN	with
glycine	NN	glycine
alone	RB	alone
.	.	.
</s>
<s type="decl">
Further	JJR	further
studies	NNS	study
are	VBP	be
required	VBN	require
to	TO	to
clarify	VB	clarify
the	DT	the
mechanism	NN	mechanism
underlying	VBG	underlie
the	DT	the
contribution	NN	contribution
of	IN	of
tryptophan	NN	tryptophan
to	IN	to
the	DT	the
effects	NNS	effect
of	IN	of
glycine	NN	glycine
on	IN	on
uric	NN	uric
acid	NN	acid
excretion	NN	excretion
.	.	.
</s>
</p>
<p>
<s type="sub">
Among	IN	among
the	DT	the
limitations	NNS	limitation
in	IN	in
the	DT	the
current	JJ	current
clinical	JJ	clinical
study	NN	study
,	,	,
the	DT	the
modest	JJ	modest
sample	NN	sample
size	NN	size
(	-LRB-	(
<hi rend="italic">
n	NN	n
</hi>
=	SYM	=
16	CD	16
)	-RRB-	)
might	MD	might
have	VB	have
reduced	VBN	reduce
the	DT	the
statistical	JJ	statistical
power	NN	power
and	CC	and
increased	VBD	increase
the	DT	the
risk	NN	risk
of	IN	of
type	NN	type
II	CD	II
error	NN	error
,	,	,
particularly	RB	particularly
regarding	VBG	regard
the	DT	the
statistical	JJ	statistical
differences	NNS	difference
in	IN	in
multiple	JJ	multiple
comparisons	NNS	comparison
between	IN	between
the	DT	the
glycine	NN	glycine
and	CC	and
glycine	NN	glycine
+	SYM	+
tryptophan	NN	tryptophan
groups	NNS	group
.	.	.
</s>
<s type="decl">
Furthermore	RB	furthermore
,	,	,
the	DT	the
current	JJ	current
study	NN	study
included	VBD	include
only	RB	only
male	JJ	male
subjects	NNS	subject
because	IN	because
of	IN	of
the	DT	the
known	VBN	know
effects	NNS	effect
of	IN	of
sex	NN	sex
differences	NNS	difference
on	IN	on
serum	NN	serum
uric	NN	uric
acid	NN	acid
levels	NNS	level
.	.	.
</s>
<s type="decl">
Further	JJ	further
studies	NNS	study
are	VBP	be
therefore	RB	therefore
needed	VBN	need
,	,	,
although	IN	although
our	PRP$	our
preliminary	JJ	preliminary
findings	NNS	finding
suggested	VBD	suggest
that	IN	that
there	EX	there
were	VBD	be
no	DT	no
effective	JJ	effective
differences	NNS	difference
between	IN	between
males	NNS	male
and	CC	and
females	NNS	female
in	IN	in
response	NN	response
to	IN	to
glycine	NN	glycine
and	CC	and
tryptophan	NN	tryptophan
supplementation	NN	supplementation
(	-LRB-	(
data	NNS	datum
not	RB	not
shown	VBN	show
)	-RRB-	)
.	.	.
</s>
</p>
</text>